Corvus Pharmaceuticals Inc (NAS:CRVS)
$ 1.93 -0.11 (-5.39%) Market Cap: 120.72 Mil Enterprise Value: 104.37 Mil PE Ratio: 0 PB Ratio: 2.84 GF Score: 41/100

Corvus Pharmaceuticals Inc R&D Symposium Transcript

May 10, 2022 / 01:00PM GMT
Release Date Price: $1.22 (+8.93%)
Richard A. Miller
Corvus Pharmaceuticals, Inc. - Co-Founder, President, CEO & Chairman of the Board

I think we should get started. We have a lot to cover today. We're really excited to be back in New York, able to meet all of you and to review all the programs at Corvus.

First of all, can everybody hear me? Good. I'm not going to use that podium because I don't know, it's kind of boring and I'm afraid I'll fall off of it. So I think that this enables me to move around and make some eye contact.

So my name is Richard Miller. I'm the CEO of Corvus Pharmaceuticals. And we have a really packed agenda today. So I would like to get started.

Next slide is our forward-looking statements, which you can review at your leisure. I'm very pleased today to be joined by 3 other speakers. I will be presiding at the meeting. But really, that's -- that's my pleasure to be associated with these 3 individuals. First, we have Dr. Neel Gupta, who's an oncologist from Stanford University. Neel is a clinical assistant professor and is an expert in lymphomas. We're also joined by Erik Verner. Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot